Get the Stockscreener App
28.36
6.08%
1.625
Vera Therapeutics Inc stock is traded at $28.36, with a volume of 569.98K.
It is up +6.08% in the last 24 hours and down -15.76% over the past month.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
See More
Previous Close:
$26.74
Open:
$27.28
24h Volume:
569.98K
Relative Volume:
0.29
Market Cap:
$2.04B
Revenue:
Net Income/Loss:
$-368.95M
P/E Ratio:
-5.1151
EPS:
-5.5453
Net Cash Flow:
$-293.81M
1W Performance:
-4.59%
1M Performance:
-15.76%
6M Performance:
-34.72%
1Y Performance:
-8.50%
1-Day Range:
$27.13
$28.49
1-Week Range:
$26.38
$30.51
52-Week Range:
$23.05
$56.05
Vera Therapeutics Inc Stock (VERA) Company Profile
Name
Vera Therapeutics Inc
Sector
Industry
Phone
650-770-0077
Address
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
28.36 | 2.04B | 0 | -368.95M | -293.81M | -5.5453 |
VRTX
Vertex Pharmaceuticals Inc
|
509.72 | 129.19B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.78 | 94.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.11 | 82.48B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.35 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-12-26 | Initiated | Leerink Partners | Market Perform |
| Mar-11-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-16-25 | Initiated | BofA Securities | Buy |
| Aug-04-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-05-25 | Resumed | H.C. Wainwright | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Jan-28-25 | Initiated | Goldman | Buy |
| Nov-21-24 | Initiated | Wells Fargo | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-25-24 | Initiated | Oppenheimer | Outperform |
| Jan-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-23 | Initiated | Raymond James | Outperform |
| Nov-10-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-16-23 | Initiated | Guggenheim | Buy |
| Jan-04-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-04-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-12-22 | Initiated | JP Morgan | Overweight |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-22 | Initiated | Wedbush | Outperform |
View All
Vera Therapeutics Inc Stock (VERA) Latest News
Vera Therapeutics, Inc. (VERA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Five new hires at Vera Therapeutics received share options and awards that vest over four years. - Stock Titan
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - globenewswire.com
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Vera Therapeutics (NASDAQ: VERA) CEO exercises options and sells shares under preset trading plan - Stock Titan
Vera Therapeutics CFO Young Joseph R Exercises 5,000 Stock Options at $3.94 (NASDAQ: VERA) - Kalkine Media
Vera Therapeutics (VERA) finance SVP adds 5,000 shares - Stock Titan
Vera Therapeutics at Cantor Fitzgerald conference: launch gains traction By Investing.com - Investing.com Canada
Vera Therapeutics at Cantor Fitzgerald conference: launch gains traction By Investing.com - Investing.com India
Centrus Announces Proposed Public Underwritten Offering of Class A Common Stock and Warrants - Yahoo Finance
Vera Therapeutics CEO Marshall Fordyce Executes 18,500 Share Sale Under 10b5-1 Trading Plan - Kalkine Media
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Discipline and Rules-Based Execution in VERA Response - Stock Traders Daily
Vera Therapeutics (NASDAQ: VERA) insider to sell tens of thousands of shares - Stock Titan
Vera Therapeutics stock gains after fresh analyst support - ad-hoc-news.de
Vera Therapeutics to Participate at Upcoming Investor Conferences - manilatimes.net
Vera Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewswire
Vera Therapeutics to Participate at Upcoming Investor Conferences - Yahoo Finance
Vera Therapeutics options activity points to institutional bullish call spread on September strikes - investing.com
Nancy Lee Boman Net Worth (2026) - GuruFocus
Vera Therapeutics (NASDAQ:VERA): What Could Drive the Next Move? - Kalkine Media
What Vera Therapeutics (VERA)'s Widening Losses and Cash Burn Mean For Shareholders - Sahm
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
H.C. Wainwright Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $90 - Moomoo
What Vera Therapeutics (VERA)'s Widening Losses and Cash Burn Mean For Shareholders - simplywall.st
Bank of America Corp DE Has $23.72 Million Stake in Vera Therapeutics, Inc. $VERA - MarketBeat
Vera Therapeutics upgraded to Buy after FDA nod for TRUTAKNA and positive kidney function data. - Pluang
Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy (NASDAQ:VERA) - Seeking Alpha
Wedbush Reiterates Neutral Rating for Vera Therapeutics (NASDAQ:VERA) - MarketBeat
J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $76 - Moomoo
Vera Therapeutics Stock (VERA) Opinions on Positive eGFR Data Release - Quiver Quantitative
Vera Therapeutics Shares Up 9.7% as $425,000 Drug Launch Puts Focus on Cash Reserves - TechStock²
Vera Therapeutics Climbs as Investors React to TRUTAKNA Launch Progress and Near-Term IgAN Milestones - Quiver Quantitative
Kynam Capital (VERA) now holds 4.01% beneficial stake in Vera Therapeutics - Stock Titan
Vera Therapeutics (NASDAQ:VERA) Shares Gap UpHere's Why - MarketBeat
HC Wainwright Has Positive Estimate for VERA Q3 Earnings - MarketBeat
Vera stock rises on FDA review for kidney drug (VERA:NASDAQ) - Seeking Alpha
Is Vera Therapeutics (VERA) Undervalued On FDA Approval For TRUTAKNA? - Sahm
(VERA) Volatility Zones as Tactical Triggers - Stock Traders Daily
Vera Therapeutics president and CEO Marshall Fordyce sells $701,769 in stock - Investing.com
Vera Therapeutics president and CEO Marshall Fordyce sells $1.96m in stock - Investing.com
Vera Therapeutics CEO Marshall Fordyce sells $679,747 in stock - investing.com
Vera Therapeutics president and CEO Marshall Fordyce sells $1.96m in stock - Investing.com Nigeria
Vera Therapeutics president and CEO Marshall Fordyce sells $701,769 in stock - Investing.com Canada
Vera Therapeutics president and CEO Marshall Fordyce sells $1.96m in stock - Investing.com South Africa
Vera Therapeutics president and CEO Marshall Fordyce sells $701,769 in stock - Investing.com South Africa
Vera Therapeutics president and CEO Marshall Fordyce sells $1.96m in stock - Investing.com India
Vera Therapeutics president and CEO Marshall Fordyce sells $701,769 in stock - Investing.com Australia
Vera Therapeutics president and CEO Marshall Fordyce sells $701,769 in stock - Investing.com India
Vera Therapeutics CEO Marshall Fordyce sells $679,747 in stock - Investing.com
Vera Therapeutics Inc Stock (VERA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vera Therapeutics Inc Stock (VERA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Fordyce Marshall | PRESIDENT AND CEO |
Sep 15 '26 |
Sale |
37.00 |
18,500 |
684,500 |
235,244 |
| Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR |
Sep 11 '26 |
Option Exercise |
3.94 |
5,000 |
19,698 |
80,754 |
| Fordyce Marshall | PRESIDENT AND CEO |
Sep 02 '26 |
Sale |
35.12 |
18,500 |
649,642 |
235,244 |
| MARSHALL FORDYCE | Director |
Sep 02 '26 |
Proposed Sale |
34.23 |
64,750 |
2,216,392 |
0 |
| Fordyce Marshall | PRESIDENT AND CEO |
Sep 02 '26 |
Option Exercise |
2.90 |
18,500 |
53,591 |
253,744 |
| Fordyce Marshall | PRESIDENT AND CEO |
Jul 07 '26 |
Sale |
42.30 |
46,250 |
1,956,187 |
151,994 |
| MARSHALL FORDYCE | Director |
Jun 23 '26 |
Proposed Sale |
38.43 |
74,000 |
2,843,820 |
0 |
| Fordyce Marshall | PRESIDENT AND CEO |
Jun 23 '26 |
Sale |
37.93 |
18,500 |
701,769 |
198,244 |
| Fordyce Marshall | PRESIDENT AND CEO |
May 12 '26 |
Sale |
36.74 |
18,500 |
679,747 |
216,744 |
| MARSHALL FORDYCE | Director |
May 12 '26 |
Proposed Sale |
36.61 |
18,500 |
677,285 |
0 |
0.81%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):